{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007475","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.370398+00:00","generated_at":"2026-06-02T06:09:24.398127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroBo Q1 net loss $6.7M; first patient dosed in DA-1726 obesity trial","bullets":["Net loss of $6.7M ($1.32 per share) vs $2.6M ($0.51) in Q1 2023; R&D spend rose to $4.9M from $0.6M.","Cash $16.0M as of March 31, 2024, down from $22.4M at year-end 2023; expects runway into Q4 2024.","First patient dosed in Phase 1 SAD part of DA-1726 for obesity; top-line SAD data expected Q3 2024.","Phase 2a trial of DA-1241 for MASH fully enrolled in Part 1; Part 2 with sitagliptin enrolling; top-line data expected Q4 2024.","Appointed Marshall Woodworth as CFO (previously acting); exploring financing alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007475","json":"https://secwatch.observer/filing/0001558370-24-007475.json","markdown":"https://secwatch.observer/filing/0001558370-24-007475.md","text":"https://secwatch.observer/filing/0001558370-24-007475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/0001558370-24-007475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/nrbo-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:09:24.398127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0932660864342a1e9453cc3c10b734e2cd3f2903","claim":"MetaVia Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/0001558370-24-007475-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}